VEGFR2/CD309 Rekombinanter Antikörper

VEGFR2/CD309 Rekombinant Antikörper für WB, IHC, FC, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, FC, Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

230238D7

Kat-Nr. : 83049-4-PBS

Synonyme

KDR, VEGFR2, VEGFR2/KDR, 230238D7, CD309



Geprüfte Anwendungen

Produktinformation

83049-4-PBS bindet in WB, IHC, FC, Indirect ELISA VEGFR2/CD309 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen VEGFR2/CD309 fusion protein Eg0218
Vollständiger Name kinase insert domain receptor (a type III receptor tyrosine kinase)
Berechnetes Molekulargewicht 152 kDa
Beobachtetes Molekulargewicht150 kDa, 230 kDa
GenBank-ZugangsnummerNM_002253
Gene symbol KDR
Gene ID (NCBI) 3791
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

KDR, also named as VEGFR-2, FLK1 and CD309, is a receptor for VEGF or VEGFC. KDR which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. KDR functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.